Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response.. Transl Psychiatry. 11(1):439.. 2021.
A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: efficacy and tolerability.. J Psychiatr Res. 62:23-30.. 2015.
Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.. J Clin Psychiatry. 81(4). 2020.
Research-track programs for residents in psychiatry: a review of literature and a report of 3 Canadian experiences.. Can J Psychiatry. 59(5):268-75.. 2014.
Preferred Features of E-Mental Health Programs for Prevention of Major Depression in Male Workers: Results From a Canadian National Survey.. J Med Internet Res. 18(6):e132.. 2016.
Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment.. J Clin Psychiatry. 80(3). 2019.
MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes.. Nat Commun. 8:15497.. 2017.
Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report.. Commun Biol. 4(1):903.. 2021.
Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants.. Transl Psychiatry. 9(1):254.. 2019.
Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report.. Psychoneuroendocrinology. 132:105348.. 2021.
Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response.. Transl Psychiatry. 11(1):127.. 2021.
The Effects of an E-Mental Health Program and Job Coaching on the Risk of Major Depression and Productivity in Canadian Male Workers: Protocol for a Randomized Controlled Trial.. JMIR Res Protoc. 5(4):e218.. 2016.
Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.. BMC Psychiatry. 16:105.. 2016.
A controlled trial of the Litebook light-emitting diode (LED) light therapy device for treatment of Seasonal Affective Disorder (SAD).. BMC Psychiatry. 7:38.. 2007.
The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.. J Affect Disord. 227:542-549.. 2017.
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.. Can J Psychiatry. 61(9):540-60.. 2016.
Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report.. Transl Psychiatry. 11(1):469.. 2021.
Association between side effects and blood microRNA expression levels and their targeted pathways in patients with major depressive disorder treated by a selective serotonin reuptake inhibitor, escitalopram: a CAN-BIND-1 report.. Int J Neuropsychopharmacol.. 2019.
Adjunctive ketamine in electroconvulsive therapy: updated systematic review and meta-analysis.. Br J Psychiatry. 210(6):403-407.. 2017.